As the in vivo effects of isolated EGCG in AML have not yet been evaluated, the aim of this study was to evaluate the molecular mechanisms involved in anti-leukaemia activity of EGCG using the acute promyelocytic leukaemia (APL) model (PML/RARα). The gene discussed is RARA; the disease is acute myeloid leukemia.